Greg interviews Rick Perry, the former Governor of Texas and former U.S. Secretary of Energy and leading advocate for ibogaine.

In this episode, we discuss:

• How a former Texas governor moved from strict opposition to drugs to becoming a leading advocate for ibogaine after firsthand experience and veteran outcomes.
• Ibogaine’s impact on PTSD, opioid addiction, and traumatic brain injury, including Stanford-linked brain imaging data showing functional and structural improvement.
• How veterans are the proving ground that enabled Texas to commit $50M in public funding for ibogaine clinical trials.
• Why ibogaine requires intensive medical supervision and why rigorous trials are essential for legitimacy and scale.
• A vision where ibogaine reshapes addiction treatment, veteran care, and eventually criminal justice and homelessness policy.

Credits:

Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky
Produced by Caitlin Ner & Nico V. Rey

Find us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank

Matias interviews James (Jim) Gorman MD PhD from the Wyss Institute. Jim is Principal Investigator on the Wyss Institute Brain Targeting Program (BTP). Jim leads a team developing new approaches to transport drugs through the blood brain barrier (BBB) into the CNS.

In this episode, we discuss:

• Why the BBB blocks most modern drugs from entering the brain, creating the biggest bottleneck in neuro
• How brain shuttles hijack natural transport pathways like the transferrin receptor to move drugs across the BBB
• How new modalities that reach the brain can potentially treat diseases like Alzheimer’s, Parkinson’s, ALS, and lysosomal disorders
• Why delivery route of shuttles enable IV or subcutaneous dosing instead of invasive intrathecal injections
• How early data shows that shuttle-enabled antibodies clear amyloid faster, at lower doses, and with fewer side effects
• How the field is accelerating through a pre-competitive consortium model that lets multiple companies share shuttle platforms

Credits:

Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky
Produced by Caitlin Ner & Nico V. Rey

Find us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank

Greg and Matias interview Luis Voloch, CEO and Co-Founder of Jimini Health, an AI behavioral health company. He previously co-founded and served as CTO of Immunai, where he applied machine learning to immunology and drug discovery.

In this episode, we discuss:

• How LLMs expand the scope of machine learning from rule-based tasks to open-ended reasoning and dialogue
• Why healthcare adoption is tiered, beginning with clinician-facing AI scribes and moving toward patient-facing companies with human-in-the-loop to enhance quality of care
• Why human oversight is essential and how AI can augment complex clinical work instead of replacing it
• The competitive advantage from workflows, data, and trust via purpose built AI systems
• The path toward precision psychiatry, where continuous, language-based interactions can generate rich behavioral data to inform diagnostics, treatment, and drug discovery

Credits:

Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky
Produced by Caitlin Ner & Nico V. Rey

Find us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank